BioScrip Inc Receives a Buy from Barrington


In a report released today, Michael Petusky from Barrington maintained a Buy rating on BioScrip Inc (NASDAQ: BIOS), with a price target of $3.50. The company’s shares closed yesterday at $2.55.

Petusky noted:

“We continue to model further improvement in gross margin over the next couple of years.”

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 12.9% and a 58.0% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

BioScrip Inc has an analyst consensus of Strong Buy, with a price target consensus of $3.42.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.39 and a one-year low of $1.62. Currently, BioScrip Inc has an average volume of 757K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts